marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q1
added 06-29-2023
Idera Pharmaceuticals Balance Sheet 2011-2024 | IDRA
Annual Balance Sheet Idera Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-11.5 M | -31.8 M | -32.3 M | -39 M | -71.4 M | -112 M | -80.2 M | -25.8 M | -19.1 M | -26.3 M | -10.1 M | -24.6 M |
Long Term Debt |
326 K | 549 K | - | - | - | - | 209 K | 501 K | 742 K | - | - | - |
Long Term Debt Current |
234 K | 209 K | 191 K | 163 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 127 M | 4.14 M | 11 K | 613 K | 529 K | 1.88 M | 978 K | 5 K | 65 K | 7.49 M |
Total Current Liabilities |
21.4 M | 4.86 M | 7.03 M | 54.5 M | 9.02 M | 10.1 M | 9.35 M | 6.82 M | 7.05 M | 4.41 M | 4.13 M | 6.08 M |
Total Liabilities |
62.2 M | 5.41 M | 134 M | 58.7 M | 9.03 M | 10.7 M | 9.88 M | 8.69 M | 8.02 M | 4.42 M | 4.2 M | 13.6 M |
Deferred Revenue |
- | - | - | - | - | 566 K | 1.11 M | 1.11 M | - | - | - | - |
Retained Earnings |
-759 M | -735 M | -834 M | -721 M | -664 M | -604 M | -538 M | -500 M | -452 M | -413 M | -395 M | -375 M |
Total Assets |
101 M | 34.9 M | 42.4 M | 47.5 M | 73 M | 118 M | 113 M | 92.3 M | 51.4 M | 36.9 M | 10.8 M | 25.6 M |
Cash and Cash Equivalents |
12 M | 32.5 M | 33.2 M | 40 M | 71.4 M | 113 M | 80.7 M | 26.6 M | 20 M | 26.3 M | 10.1 M | 24.6 M |
Book Value |
38.9 M | 29.5 M | -91.2 M | -11.2 M | 64 M | 108 M | 103 M | 83.6 M | 43.4 M | 32.5 M | 6.63 M | 12 M |
Total Shareholders Equity |
11.8 M | 29.5 M | -91.2 M | -11.2 M | 64 M | 108 M | 103 M | 83.6 M | 43.4 M | 32.5 M | 706 K | 12 M |
All numbers in USD currency
Quarterly Balance Sheet Idera Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
271 K | 326 K | 5.94 M | 438 K | 494 K | 549 K | 603 K | 656 K | 708 K | 758 K | 758 K | 758 K | 758 K | 899 K | 899 K | 899 K | 899 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 195 K | 217 K | - |
Total Liabilities |
55.9 M | 62.2 M | 53.7 M | 5.17 M | 4.29 M | 5.41 M | 6.17 M | 6.68 M | 5.7 M | 134 M | 134 M | 134 M | 134 M | 58.7 M | 58.7 M | 58.7 M | 58.7 M | 9.03 M | 9.03 M | 9.03 M | 9.03 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 9.88 M | 9.88 M | 9.88 M | 9.88 M | 8.69 M | 8.69 M | 8.69 M | 8.69 M | 8.02 M | 8.02 M | 8.02 M | 8.02 M | 4.42 M | 4.42 M | 4.42 M | 4.42 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 7.65 M | 7.65 M | 7.65 M | 7.65 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 94 K | 235 K | 376 K | 566 K | 563 K | 563 K | 985 K | 1.11 M | 1.11 M | 1.11 M | 1.11 M | 1.11 M | 1.11 M | 1.11 M | 1.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-781 M | -759 M | -748 M | -745 M | -740 M | -735 M | -731 M | -725 M | -718 M | -834 M | -834 M | -834 M | -834 M | -721 M | -721 M | -721 M | -721 M | -664 M | -664 M | -664 M | -664 M | -604 M | -604 M | -604 M | -604 M | -538 M | -538 M | -538 M | -538 M | -500 M | -500 M | -500 M | -500 M | -452 M | -452 M | -452 M | -452 M | -413 M | -413 M | -413 M | -413 M | -395 M | -395 M | -395 M | -395 M | -375 M | -375 M | -375 M | -375 M |
Total Assets |
78.5 M | 101 M | 104 M | 26.3 M | 30.1 M | 34.9 M | 39.2 M | 44.4 M | 48 M | 42.4 M | 42.4 M | 42.4 M | 42.4 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 73 M | 73 M | 73 M | 73 M | 118 M | 118 M | 118 M | 118 M | 113 M | 113 M | 113 M | 113 M | 92.3 M | 92.3 M | 92.3 M | 92.3 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 36.9 M | 36.9 M | 36.9 M | 36.9 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 25.6 M | 25.6 M | 25.6 M | 25.6 M |
Cash and Cash Equivalents |
2.12 M | 12 M | 26.8 M | 24.5 M | 28 M | 32.5 M | 36.6 M | 40.6 M | 44.5 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 40 M | 40 M | 40 M | 40 M | 71.4 M | 71.4 M | 71.4 M | 71.4 M | 113 M | 113 M | 113 M | 113 M | 80.7 M | 80.7 M | 80.7 M | 80.7 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 20 M | 20 M | 20 M | 20 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M |
Book Value |
22.5 M | 38.9 M | 49.9 M | 21.1 M | 25.8 M | 29.5 M | 33 M | 37.7 M | 42.3 M | -91.2 M | -91.2 M | -91.2 M | -91.2 M | -11.2 M | -11.2 M | -11.2 M | -11.2 M | 64 M | 64 M | 64 M | 64 M | 108 M | 108 M | 108 M | 108 M | 103 M | 103 M | 103 M | 103 M | 83.6 M | 83.6 M | 83.6 M | 83.6 M | 43.4 M | 43.4 M | 43.4 M | 43.4 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 6.63 M | 6.63 M | 6.63 M | 6.63 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M |
Total Shareholders Equity |
22.5 M | 11.8 M | 20.8 M | 21.1 M | 25.8 M | 29.5 M | 33 M | 37.7 M | 42.3 M | -91.2 M | -91.2 M | -91.2 M | -91.2 M | -11.2 M | -11.2 M | -11.2 M | -11.2 M | 64 M | 64 M | 64 M | 64 M | 108 M | 108 M | 108 M | 108 M | 103 M | 103 M | 103 M | 103 M | 83.6 M | 83.6 M | 83.6 M | 83.6 M | 43.4 M | 43.4 M | 43.4 M | 43.4 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 706 K | 706 K | 706 K | 706 K | 12 M | 12 M | 12 M | 12 M |
All numbers in USD currency